Jehu S Mathew1, Michael C Sachs2, Ronit Katz2, Kristen K Patton2, Susan R Heckbert2, Andrew N Hoofnagle2, Alvaro Alonso2, Michel Chonchol2, Rajat Deo2, Joachim H Ix2, David S Siscovick2, Bryan Kestenbaum2, Ian H de Boer2. 1. From the Division of Cardiology (J.S.M., K.K.P.), Division of Nephrology and Kidney Research Institute (J.S.M., M.C.S., R.K., B.K., I.H.d.B.), Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology (S.R.H., D.S.S.), Department of Epidemiology (S.R.H., B.K., I.H.d.B.), and Department of Laboratory Medicine (A.N.H.), University of Washington, Seattle; Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis (A.A.); Division of Renal Diseases and Hypertension, University of Colorado, Denver (M.C.); Division of Cardiology, Electrophysiology Section, University of Pennsylvania, Philadelphia (R.D.); and Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, and San Diego VA Healthcare System, San Diego (J.H.I.). jmathew@cardiology.washington.edu. 2. From the Division of Cardiology (J.S.M., K.K.P.), Division of Nephrology and Kidney Research Institute (J.S.M., M.C.S., R.K., B.K., I.H.d.B.), Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology (S.R.H., D.S.S.), Department of Epidemiology (S.R.H., B.K., I.H.d.B.), and Department of Laboratory Medicine (A.N.H.), University of Washington, Seattle; Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis (A.A.); Division of Renal Diseases and Hypertension, University of Colorado, Denver (M.C.); Division of Cardiology, Electrophysiology Section, University of Pennsylvania, Philadelphia (R.D.); and Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, and San Diego VA Healthcare System, San Diego (J.H.I.).
Abstract
BACKGROUND: Fibroblast growth factor-23 (FGF-23) is a hormone that promotes urinary phosphate excretion and regulates vitamin D metabolism. Circulating FGF-23 concentrations increase markedly in chronic kidney disease and are associated with increased risk of clinical cardiovascular events. FGF-23 may promote atrial fibrillation (AF) by inducing left ventricular hypertrophy and diastolic and left atrial dysfunction. METHODS AND RESULTS: We tested the associations of circulating FGF-23 concentration with incident AF among 6398 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) and 1350 participants in the Cardiovascular Health Study (CHS), all free of clinical cardiovascular disease at baseline. Over a median of 7.7 and 8.0 years of follow-up, we observed 291 and 229 incident AF events in MESA and CHS, respectively. In multivariable Cox proportional hazards models, each 2-fold-higher FGF-23 concentration was associated with a 41% higher risk of incident AF in MESA (hazard ratio, 1.41; 95% confidence interval, 1.13-1.76; P=0.003) and a 30% higher risk of incident AF in CHS (hazard ratio, 1.30; 95% confidence interval, 1.05-1.61; P=0.016) after adjustment for potential confounding characteristics, including kidney disease. Serum phosphate concentration was significantly associated with incident AF in MESA (hazard ratio, 1.15 per 0.5 mg/dL; 95% confidence interval, 1.02-1.31; P=0.023) but not CHS. In MESA, an association of low estimated glomerular filtration rate with incident AF was partially attenuated by adjustment for FGF-23. CONCLUSION: Higher circulating FGF-23 concentration is associated with incident AF and may, in part, explain the link between chronic kidney disease and AF.
BACKGROUND:Fibroblast growth factor-23 (FGF-23) is a hormone that promotes urinary phosphate excretion and regulates vitamin D metabolism. Circulating FGF-23 concentrations increase markedly in chronic kidney disease and are associated with increased risk of clinical cardiovascular events. FGF-23 may promote atrial fibrillation (AF) by inducing left ventricular hypertrophy and diastolic and left atrial dysfunction. METHODS AND RESULTS: We tested the associations of circulating FGF-23 concentration with incident AF among 6398 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) and 1350 participants in the Cardiovascular Health Study (CHS), all free of clinical cardiovascular disease at baseline. Over a median of 7.7 and 8.0 years of follow-up, we observed 291 and 229 incident AF events in MESA and CHS, respectively. In multivariable Cox proportional hazards models, each 2-fold-higher FGF-23 concentration was associated with a 41% higher risk of incident AF in MESA (hazard ratio, 1.41; 95% confidence interval, 1.13-1.76; P=0.003) and a 30% higher risk of incident AF in CHS (hazard ratio, 1.30; 95% confidence interval, 1.05-1.61; P=0.016) after adjustment for potential confounding characteristics, including kidney disease. Serum phosphate concentration was significantly associated with incident AF in MESA (hazard ratio, 1.15 per 0.5 mg/dL; 95% confidence interval, 1.02-1.31; P=0.023) but not CHS. In MESA, an association of low estimated glomerular filtration rate with incident AF was partially attenuated by adjustment for FGF-23. CONCLUSION: Higher circulating FGF-23 concentration is associated with incident AF and may, in part, explain the link between chronic kidney disease and AF.
Authors: Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix Journal: Ann Intern Med Date: 2010-05-18 Impact factor: 25.391
Authors: Jason P Linefsky; Kevin D O'Brien; Ronit Katz; Ian H de Boer; Eddy Barasch; Nancy S Jenny; David S Siscovick; Bryan Kestenbaum Journal: J Am Coll Cardiol Date: 2011-07-12 Impact factor: 24.094
Authors: Michiel Rienstra; Steven A Lubitz; Michael L Zhang; Rebecca R Cooper; Patrick T Ellinor Journal: J Am Coll Cardiol Date: 2011-06-21 Impact factor: 24.094
Authors: Sarah Seiler; Birgit Reichart; Daniel Roth; Eric Seibert; Danilo Fliser; Gunnar H Heine Journal: Nephrol Dial Transplant Date: 2010-06-03 Impact factor: 5.992
Authors: Alvaro Alonso; Faye L Lopez; Kunihiro Matsushita; Laura R Loehr; Sunil K Agarwal; Lin Y Chen; Elsayed Z Soliman; Brad C Astor; Josef Coresh Journal: Circulation Date: 2011-06-06 Impact factor: 29.690
Authors: Poyyapakkam R Srivaths; Stuart L Goldstein; Douglas M Silverstein; Rajesh Krishnamurthy; Eileen D Brewer Journal: Pediatr Nephrol Date: 2011-02-27 Impact factor: 3.714
Authors: Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol Journal: J Am Soc Nephrol Date: 2011-09-07 Impact factor: 10.121
Authors: Rupal Mehta; Xuan Cai; Jungwha Lee; Julia J Scialla; Nisha Bansal; James H Sondheimer; Jing Chen; L Lee Hamm; Ana C Ricardo; Sankar D Navaneethan; Rajat Deo; Mahboob Rahman; Harold I Feldman; Alan S Go; Tamara Isakova; Myles Wolf Journal: JAMA Cardiol Date: 2016-08-01 Impact factor: 14.676
Authors: Bhupesh Panwar; Nancy S Jenny; Virginia J Howard; Virginia G Wadley; Paul Muntner; Brett M Kissela; Suzanne E Judd; Orlando M Gutiérrez Journal: Stroke Date: 2015-01-06 Impact factor: 7.914
Authors: Ravi B Patel; Hongyan Ning; Ian H de Boer; Bryan Kestenbaum; João A C Lima; Rupal Mehta; Norrina B Allen; Sanjiv J Shah; Donald M Lloyd-Jones Journal: Circ Cardiovasc Imaging Date: 2020-11-09 Impact factor: 7.792
Authors: Rupal Mehta; Gui Shuang Ying; Samuel Houston; Tamara Isakova; Lisa Nessel; Akinlolu Ojo; Alan Go; Jim Lash; John Kusek; Juan Grunwald; Myles Wolf Journal: Nephrol Dial Transplant Date: 2015-04-24 Impact factor: 5.992